Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status approved
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 57884-0006; 63323-142; 0143-9531; 0338-3991; 15308-0411; 0338-3993; 65124-0001; 0143-9530; 10019-926; 10019-927; 10019-929
UNII UM20QQM95Y
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Left ventricular failure02.05.02.001--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000168%
Leukoencephalopathy17.13.02.003--
Leukopenia01.02.02.0010.000168%Not Available
Logorrhoea19.19.02.001; 17.02.08.006--Not Available
Lung consolidation22.01.02.0100.000246%Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Metabolic acidosis14.01.01.003--Not Available
Methaemoglobinaemia01.05.01.002--
Movement disorder17.01.02.010--Not Available
Mucosal inflammation08.01.06.0020.000783%Not Available
Mucosal ulceration08.01.06.0030.000112%Not Available
Muscle twitching15.05.03.005--Not Available
Musculoskeletal pain15.03.04.0070.000112%
Mutism19.19.01.001; 17.02.08.007--Not Available
Myalgia15.05.02.001--
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.000112%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocarditis02.04.03.001--
Myoclonus17.02.05.0080.000280%Not Available
Nail disorder23.02.05.0020.000112%
Nausea07.01.07.0010.001130%
Necrosis24.04.02.006; 08.03.03.001--Not Available
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.001--Not Available
Nephrogenic diabetes insipidus20.05.03.010; 14.05.07.0020.000224%Not Available
Nephropathy20.05.03.001--Not Available
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene